Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenicor Medical Systems ABXSAT:ZENI -1.56%45 3-Year ROIIC % is 10.93 as of Dec. 2025, which is 272% above its 10-year median of 2.94. GuruFocus rates XSAT:ZENI with a GF Score™ of 45/100 and a GF Value™ of kr1.03 (Fairly Valued). The stock has 7 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Zenicor Medical Systems AB ranks better than 62.06% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Zenicor Medical Systems AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 10.93%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Zenicor Medical Systems AB's 3-Year ROIIC % or its related term are showing as below:
XSAT:ZENI's 3-Year ROIIC % is ranked better than 62.06% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.385
vs XSAT:ZENI: 10.93
Zenicor Medical Systems AB (XSAT:ZENI) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Zenicor Medical Systems AB 3-Year ROIIC % Related Terms
Zenicor Medical Systems AB 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ZENI vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Zenicor Medical Systems AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenicor Medical Systems AB 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zenicor Medical Systems AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Zenicor Medical Systems AB's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.114 (Dec. 2025) - -0.765 (Dec. 2022) )
/
( 69.643 (Dec. 2025) - 43.307 (Dec. 2022) )
=
2.879
/
26.336
=
10.93%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Zenicor Medical Systems AB (XSAT:ZENI) has a 3-Year ROIIC % of 10.93 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zenicor Medical Systems AB and its competitors. This is 272% above median its historical median of 2.94. According to the industry distribution chart, Zenicor Medical Systems AB ranks #302 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 37.9%.
Is Zenicor Medical Systems AB's 3-Year ROIIC % too high?
Zenicor Medical Systems AB's current 3-Year ROIIC % of 10.93 is 272% above median its 10-year median of 2.94. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.39. Zenicor Medical Systems AB's value of 10.93 is 689.2% above this industry median. Based on the distribution chart, Zenicor Medical Systems AB ranks #302 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zenicor Medical Systems AB has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zenicor Medical Systems AB's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zenicor Medical Systems AB ranks #302 out of 796 companies for 3-Year ROIIC %. This puts Zenicor Medical Systems AB in the upper half of its industry. The industry median 3-Year ROIIC % is 1.39. Zenicor Medical Systems AB's value of 10.93 is 689.2% above this benchmark. While the company's 10-year median is 2.94 vs. the industry median of 1.39, Zenicor Medical Systems AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.39, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenicor Medical Systems AB's current 3-Year ROIIC % of 10.93 is 689.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zenicor Medical Systems AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenicor Medical Systems AB's current 3-Year ROIIC % is 10.93, which is 272% above median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenicor Medical Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Zenicor Medical Systems AB (XSAT:ZENI) is currently considered Fairly Valued. The stock's GF Value™ is kr1.03, compared to a current price of kr0.95 — trading 8.3% below its estimated fair value. The current 3-Year ROIIC % is 10.93, which is 272% above median its 10-year median of 2.94 and 689.2% above the Medical Devices & Instruments industry median of 1.39. Zenicor Medical Systems AB's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Zenicor Medical Systems AB (XSAT:ZENI), the current 3-Year ROIIC % is 10.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenicor Medical Systems AB (XSAT:ZENI) Overvalued in 2026?
Based on GuruFocus' analysis, Zenicor Medical Systems AB stock appears to be undervalued.
The current stock price of kr0.95 is trading 8.3% below its estimated GF Value™ of kr1.03.
GuruFocus considers Zenicor Medical Systems AB to be Fairly Valued.
Key valuation signals for XSAT:ZENI:
3-Year ROIIC %: 10.93 (272% above median its 10-year median of 2.94)
GF Value™: kr1.03 vs. price of kr0.95 (8.3% below fair value)
Industry Position: 689.2% above the Medical Devices & Instruments median (#302 of 796)
No single metric tells the full story. See the XSAT:ZENI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ZENI has been successfully added to your 
